Literature DB >> 10187828

Impaired membrane transport in methotrexate-resistant CCRF-CEM cells involves early translation termination and increased turnover of a mutant reduced folate carrier.

S C Wong1, L Zhang, T L Witt, S A Proefke, A Bhushan, L H Matherly.   

Abstract

The basis for impaired reduced folate carrier (RFC) activity in methotrexate-resistant CCRF-CEM (CEM/Mtx-1) cells was examined. Parental and CEM/Mtx-1 cells expressed identical levels of the 3. 1-kilobase RFC transcript. A approximately 85-kDa RFC protein was detected in parental cells by photoaffinity labeling and on Western blots with RFC-specific antiserum. In CEM/Mtx-1 cells, RFC protein was undetectable. By reverse transcriptase-polymerase chain reaction and sequence analysis, G to A point mutations were identified in CEM/Mtx-1 transcripts at positions 130 (P1; changes glycine 44 --> arginine) and 380 (P2; changes serine 127 --> asparagine). A 4-base pair (CATG) insertion detected at position 191 (in 19-30% of cDNA clones) resulted in a frameshift and early translation termination. Wild-type RFC was also detected (0-9% of clones). Wild-type RFC and double-mutated RFC (RFCP1+P2) cDNAs were transfected into transport-impaired K562 and Chinese hamster ovary cells. Although RFC transcripts paralleled wild-type protein, for the RFCP1+P2 transfectants, disproportionately low RFCP1+P2 protein was detected. This reflected an increased turnover of RFCP1+P2 over wild-type RFC. RFCP1+P2 did not restore methotrexate transport; however, uptake was partially restored by constructs with single mutations at the P1 or P2 loci. Cumulatively, our results show that loss of transport function in CEM/Mtx-1 cells results from complete loss of RFC protein due to early translation termination and increased turnover of a mutant RFC protein.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10187828     DOI: 10.1074/jbc.274.15.10388

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  24 in total

1.  Cytoplasmic domains of the reduced folate carrier are essential for trafficking, but not function.

Authors:  Heather Sadlish; Frederick M R Williams; Wayne F Flintoff
Journal:  Biochem J       Date:  2002-06-15       Impact factor: 3.857

2.  Potent dual thymidylate synthase and dihydrofolate reductase inhibitors: classical and nonclassical 2-amino-4-oxo-5-arylthio-substituted-6-methylthieno[2,3-d]pyrimidine antifolates.

Authors:  Aleem Gangjee; Yibin Qiu; Wei Li; Roy L Kisliuk
Journal:  J Med Chem       Date:  2008-09-25       Impact factor: 7.446

3.  Structure and function of the reduced folate carrier a paradigm of a major facilitator superfamily mammalian nutrient transporter.

Authors:  Larry H Matherly; Zhanjun Hou
Journal:  Vitam Horm       Date:  2008       Impact factor: 3.421

4.  SLC19A1 pharmacogenomics summary.

Authors:  Sook Wah Yee; Li Gong; Ilaria Badagnani; Kathleen M Giacomini; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2010-11       Impact factor: 2.089

5.  Synthesis of classical, four-carbon bridged 5-substituted furo[2,3-d]pyrimidine and 6-substituted pyrrolo[2,3-d]pyrimidine analogues as antifolates.

Authors:  Aleem Gangjee; Yibin Zeng; John J McGuire; Roy L Kisliuk
Journal:  J Med Chem       Date:  2005-08-11       Impact factor: 7.446

6.  Identification of the minimal functional unit of the homo-oligomeric human reduced folate carrier.

Authors:  Zhanjun Hou; Christina Cherian; Joseph Drews; Jianmei Wu; Larry H Matherly
Journal:  J Biol Chem       Date:  2009-12-17       Impact factor: 5.157

7.  Restoration of high-level transport activity by human reduced folate carrier/ThTr1 thiamine transporter chimaeras: role of the transmembrane domain 6/7 linker region in reduced folate carrier function.

Authors:  Xiang Y Liu; Teah L Witt; Larry H Matherly
Journal:  Biochem J       Date:  2003-01-01       Impact factor: 3.857

8.  Design, synthesis, and X-ray crystal structure of classical and nonclassical 2-amino-4-oxo-5-substituted-6-ethylthieno[2,3-d]pyrimidines as dual thymidylate synthase and dihydrofolate reductase inhibitors and as potential antitumor agents.

Authors:  Aleem Gangjee; Wei Li; Roy L Kisliuk; Vivian Cody; Jim Pace; Jennifer Piraino; Jennifer Makin
Journal:  J Med Chem       Date:  2009-08-13       Impact factor: 7.446

9.  Resistance to multiple novel antifolates is mediated via defective drug transport resulting from clustered mutations in the reduced folate carrier gene in human leukaemia cell lines.

Authors:  Lilah Rothem; Ilan Ifergan; Yotam Kaufman; David G Priest; Gerrit Jansen; Yehuda G Assaraf
Journal:  Biochem J       Date:  2002-11-01       Impact factor: 3.857

10.  Design, synthesis, and biological evaluation of classical and nonclassical 2-amino-4-oxo-5-substituted-6-methylpyrrolo[3,2-d]pyrimidines as dual thymidylate synthase and dihydrofolate reductase inhibitors.

Authors:  Aleem Gangjee; Wei Li; Jie Yang; Roy L Kisliuk
Journal:  J Med Chem       Date:  2007-12-12       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.